BioCentury | Dec 6, 2019
Targets & Mechanisms

A view of immune reprogramming from ASH

ASH presentations on immune reprogramming point to new targets and mechanisms that control macrophage and T cell phenotype switching, and highlight the phenomenon's translational relevance in diseases beyond solid tumors. Strategies to convert immunosuppressive macrophage...
BioCentury | May 17, 2019
Product Development

Takeda shaves years off PRO development, brings patient voice to fatigue measures in cancer

Takeda has sidestepped the FDA qualification process for patient-reported outcomes by building on validated tools to develop a PRO for fatigue in hematologic malignancies. The approach enabled the pharma to cut its PRO development time...
BioCentury | Aug 23, 2018
Distillery Techniques

Assays and screens; imaging; drug properties

TECHNOLOGY: Cellular assays; fluorescence; drug-drug interactions A cell-based imaging method could identify targets that promote resistance to PARP inhibitors and identify synergistic combinations of PARP and other inhibitors. The method uses fluorescent microscopy in cancer...
BioCentury | Jun 20, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy A four-compound cocktail could enhance the efficiency of CRISPR-based editing in pluripotent stem cells. The method involves CRISPR-based editing in pluripotent stem cells with systems based on CRISPR from Prevotella and Francisella...
BioCentury | Feb 2, 2018
Translation in Brief

Ubiquitin choke point

Takeda has shown its first-in-class UBA1 inhibitor could safely treat cancer by blocking a protein on which virtually all cells depend for ubiquitin-mediated protein degradation, upending conventional wisdom about how to disrupt the pathway that...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Pathways emerging from ASH

A survey of the emerging molecular targets at this year’s American Society of Hematology conference indicates that while harnessing the immune system to treat cancer remains a dominant interest, processes for tuning protein levels --...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BioCentury | Nov 16, 2017
Tools & Techniques

Yeast against aggregation

...role of RSP5 in mediating α-synuclein toxicity in Science in 2013. However, Rhodes told BioCentury RSP5...
...Mass. Targets α-synuclein (SNCA) APOE4 - Apolipoprotein E ε4 HTT - Huntingtin RSP5 (NEDD4L) - NEDD4 family E3 ubiquitin-protein ligase...
...aggregates and control prion inheritance.” Cell (2017) Tardiff, D., et al. “Yeast reveal a “druggable” Rsp5/Nedd4...
BioCentury | May 31, 2017
Distillery Therapeutics

Hepatic; endocrine / metabolic

...fasting glucose and insulin levels. Next steps could include identifying inhibitors of the TMBIM1-degrading enzyme RSP5...
...BioCentury Innovations (May 18, 2017)). TARGET/MARKER/PATHWAY: Transmembrane BAX inhibitor motif containing 1 (TMBIM1); NEDD4 family E3 ubiquitin-protein ligase (RSP5; NEDD4L...
BioCentury | Dec 10, 2016
Product Development

AML advances

Treatment paradigms in most cancers have followed a predictable if sometimes slow progression from chemotherapy, to agents that target features prevalent among a classically defined cancer type, to personalized approaches targeting features specific to an...
Items per page:
1 - 10 of 42